News
Media
Conferences
Events
Partners
Publications
Resources
Biomarker Consortium
Subscribe

Your AI-Trained Oncology Knowledge Connection!

Emerging Strategies for Renal Cell Carcinoma

EP. 1: The Biology of RCC and Improved Treatment Outcomes

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 2: Tumor Biology in Favorable to Poor-Risk RCC

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 3: Improved Outcomes With Novel and Combination Therapies

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 4: Risk Assessment and Diagnostic Work-up

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 5: Newly Diagnosed RCC: KEYNOTE-426 and CheckMate-214

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 6: The Role of VEGF TKI Monotherapy

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 7: Impact of the Phase 3 CheckMate 9ER Trial on Practice

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 8: The Role of Combination Treatment in RCC

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 9: The Future Treatment Landscape of RCC

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

EP. 10: Emerging Therapies for Relapsed/Refractory MRCC

ByMichael B. Atkins, MD, Georgetown Lombardi Comprehensive Cancer Center,Robert Alter, MD, John Theurer Cancer Center

December 14th 2020

Trending on OncLive

FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC

HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts

Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC

SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma

Five Under 5: Top Oncology Videos for the Week of 1/25